Related Experiment Video
Updated: Feb 10, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
The future of chronic lymphocytic leukemia: potential directions from ASH 2017
1a Department Hematology-Oncology , Azienda Ospedaliera Pugliese-Ciaccio , Catanzaro , Italy.
Introduction:
Novel targeted therapies - including ibrutinib, venetoclax, and idelalisib - have revolutionized the treatment landscape of chronic lymphocytic leukemia (CLL). Therefore, studying combinations of novel agents (NAs) with a distinct mechanism of action and nonoverlapping toxicities is challenging. Area covered: The 2017 American Society Hematology Annual Meeting has represented a showcase for several trials combining NAs. These studies are currently evaluating the efficacy NA plus anti-CD20 monoclonal antibody, NA plus NA (with or without anti-CD20 monoclonal antibody), and NA plus chemo-immunotherapy. Expert commentary: The development of well-tolerated, highly effective combination strategies with curative potential for patients with CLL is becoming a realistic goal in CLL. From a practical standpoint, it is hard to determine which regimen will be most beneficial. Until studies of association will provide more mature results, the sequencing of NA remains a reasonable approach.
Insights
Novel targeted therapies are revolutionizing chronic lymphocytic leukemia (CLL) treatment. Combining these novel agents (NAs) presents challenges, but offers hope for curative strategies.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Novel targeted therapies like ibrutinib, venetoclax, and idelalisib have transformed chronic lymphocytic leukemia (CLL) treatment.
- Developing effective combinations of novel agents (NAs) with distinct mechanisms and non-overlapping toxicities is complex.
Purpose of the Study:
- To review novel combination strategies for CLL presented at the 2017 American Society Hematology Annual Meeting.
- To evaluate the efficacy of novel agents in combination with other treatments for CLL.
Main Methods:
- Review of clinical trials presented at the 2017 American Society Hematology Annual Meeting.
- Analysis of combination regimens including NA plus anti-CD20 monoclonal antibody, NA plus NA, and NA plus chemo-immunotherapy.
Main Results:
- Several trials combining novel agents (NAs) were presented, exploring various therapeutic combinations.
- Ongoing studies are evaluating the efficacy of these novel combinations in CLL patients.
Conclusions:
- Developing well-tolerated, highly effective combination strategies with curative potential for CLL is an emerging realistic goal.
- Sequencing of novel agents (NAs) remains a reasonable approach until more mature combination study results are available.
More Related Videos
Related Concept Videos
Standard Electrode Potentials
Potential Energy
Chemical bonds that form attractive forces between atoms also contain potential energy, called chemical energy. When a chemical reaction...
Potential Energy
Directing Effect of Substituents: meta-Directing Groups
Cell Potential and Free Energy
Thermodynamics is the branch of physics dealing with the relationship between heat and other forms of energy. In an electrochemical cell, chemical energy is converted into electrical energy.
Thus, a link can be predicted between cell potential, free energy change, and the equilibrium constant for the reaction. Cell potential can also be measured as the oxidant or the reducing strength, and similar acid-base strength measures are reflected in equilibrium...
The Resting Membrane Potential

